For another example, among the three genes HGF, MET, and EGLN2 identified in the renal cell carcinoma signaling network, HGF61 and MET62,63 have been known as potential and approved drug target genes, respectively; the third gene EGLN2 may be a promising anticancer drug target gene. The gene discussed is HGF; the disease is hereditary clear cell renal cell carcinoma.